HTD4010: Acute Pancreatitis

Acute Pancreatitis is inflammation of the pancreas.  Pancreatic damage happens when the digestive enzymes are activated before they are released into the small intestine and begin attacking the pancreas.  There are two main types of pancreatitis, acute and chronic.  Acute pancreatitis is the most common reason for hospitalization for a gastrointestinal related disease in the United States.


Despite increasing incidence, no specific drug therapy is available to ameliorate the course of the disease, and all early management strategies are mainly supportive. For example, fluid administration is the most important component of early supportive measures; nutritional support is nowadays considered a therapeutic measure instead of merely a way to provide calories to a patient with severe pancreatitis; prophylactic administration of intravenous antibiotics has been used to prevent infected necrosis and other infectious complications.


How HTD4010 Should Help in Acute Pancreatitis

HTD4010 is a 15-amino acid long synthetic peptide homologous to an active peptide sequence found within the human RegIIIα protein (PAP). The scientific rationale for the use of HTD4010 in the treatment of acute pancreatitis is based on non-clinical studies in various animal models that demonstrate the same spectrum of activities that have been demonstrated for both PAP and its active peptide sequence.


HTD4010 showed significant beneficial effects in acute pancreatitis models induced by either sodium taurocholate or caerulein. Compared to the model control group, survival rates were improved in all HTD4010 treated groups, and the normalized survival increased in a dose dependent manner (See Figure). Similar dose-dependent improvements were seen in total pancreatic damage, edema, hemorrhage, inflammation and acinar necrosis.

Market Overview
Back

That means that during the next 10 years, the field is projected to swell forty-fold from $618 million in 2016 to $25.3 billion in 2026. In 2009, there were 275,000 admissions for acute pancreatitis, and a direct annual cost of $2.6 billion. Worldwide, the incidence of acute pancreatitis is reported to be between 4.9 and 73.4 cases per 100,000. There is an increasing incidence of acute pancreatitis in the United States.

Back

We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy

收起
En

Follow Us

© 2020 HighTide Therapeutics Inc.